Evidence map›Paper›PMID 37915752›Full record

ArticleAPL bioengineering2023

Survivin as a mediator of stiffness-induced cell cycle progression and proliferation of vascular smooth muscle cells.

John C Biber, Andra Sullivan, Joseph A Brazzo, Yuna Heo, Bat-Ider Tumenbayar, Amanda Krajnik, Kerry E Poppenberg, Vincent M Tutino, Su-Jin Heo, John Kolega and 2 more

Open access · goldAbstract read
In one paragraph

Article in APL bioengineering, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Mechanotherapeutic Potential of Survivin in Glioblastoma.bioRxiv : the preprint server for biology · 2026
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

John C BiberDepartment of Pathology and Anatomical Sciences, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York 14203, USA.ORCID https://orcid.org/0009-0004-6483-1628
Andra SullivanDepartment of Biomedical Engineering, School of Engineering and Applied Sciences, University at Buffalo, Buffalo, New York 14260, USA.
Joseph A BrazzoDepartment of Pathology and Anatomical Sciences, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York 14203, USA.
Bat-Ider TumenbayarDepartment of Pharmacology and Toxicology, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York 14203, USA.ORCID https://orcid.org/0009-0008-7207-8233
Amanda KrajnikDepartment of Pathology and Anatomical Sciences, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York 14203, USA.
Su-Jin HeoDepartment of Orthopedic Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA.ORCID https://orcid.org/0000-0003-2771-5076
John KolegaDepartment of Pathology and Anatomical Sciences, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York 14203, USA.ORCID https://orcid.org/0000-0001-6933-8681
Kwonmoo LeeVascular Biology Program, Boston Children's Hospital, Boston, Massachusetts 02115, USA.ORCID https://orcid.org/0000-0001-6838-7094
University at Buffalo, State University of New York · USBoston Children's Hospital · USUniversity of Pennsylvania · US

Funding

Biomimetic Vascular Matrix for Vascular Smooth Muscle Cell Mechanobiology and PathologyR01HL163168 · NHLBI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI Yongho Bae, Su Chin Heo · 2023 to 2026
$2.2M
Biomimetic Vascular Matrix for Vascular Smooth Muscle Cell Mechanobiology and PathologyR56HL163168 · NHLBI · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI BAE, YONGHO, HEO, SU CHIN · 2022 to 2022
$640k
American Heart Association-American Stroke Association 18CDA34080415NHLBI NIH HHS R01 HL163168NHLBI NIH HHS R56 HL163168
6 · The paper itself

Abstract

Stiffened arteries are a pathology of atherosclerosis, hypertension, and coronary artery disease and a key risk factor for cardiovascular disease events. The increased stiffness of arteries triggers a phenotypic switch, hypermigration, and hyperproliferation of vascular smooth muscle cells (VSMCs), leading to neointimal hyperplasia and accelerated neointima formation. However, the mechanism underlying this trigger remains unknown. Our analyses of whole-transcriptome microarray data from mouse VSMCs cultured on stiff hydrogels simulating arterial pathology identified 623 genes that were significantly and differentially expressed (360 upregulated and 263 downregulated) relative to expression in VSMCs cultured on soft hydrogels. Functional enrichment and gene network analyses revealed that these stiffness-sensitive genes are linked to cell cycle progression and proliferation. Importantly, we found that survivin, an inhibitor of apoptosis protein, mediates stiffness-dependent cell cycle progression and proliferation as determined by gene network and pathway analyses, RT-qPCR, immunoblotting, and cell proliferation assays. Furthermore, we found that inhibition of cell cycle progression did not reduce survivin expression, suggesting that survivin functions as an upstream regulator of cell cycle progression and proliferation in response to ECM stiffness. Mechanistically, we found that the stiffness signal is mechanotransduced via the FAK-E2F1 signaling axis to regulate survivin expression, establishing a regulatory pathway for how the stiffness of the cellular microenvironment affects VSMC behaviors. Overall, our findings indicate that survivin is necessary for VSMC cycling and proliferation and plays a role in regulating stiffness-responsive phenotypes.

Identifiers

PMID37915752
PMCPMC10618027
OpenAlexW4388096398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.